Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

PZLV

Pzena U.S. Large Cap Value ETF (PZLV)

Rating:68Neutral
Price Target:$35.00▲(8.85% Upside)

PZLV’s rating suggests it is a solid but not outstanding value-focused ETF, with its performance driven by a mix of strong and weaker large-cap holdings. Strong contributors like Universal Health Services and Dollar General support the fund with solid financial performance, positive outlooks, and generally favorable technical trends, while holdings such as Baxter International and Robert Half, which face financial and operational challenges and bearish technical signals, likely weigh on the overall rating. The main risk factor is the fund’s exposure to several companies showing profitability pressures, leverage concerns, and negative price trends, which can increase volatility and downside risk for investors.

Positive Factors
Strong Overall PerformanceThe ETF has shown strong year-to-date gains, indicating that its value-focused strategy has worked well so far this year.
Healthy Top HoldingsSeveral of the largest positions, including Humana, Robert Half, Baxter International, CDW, and Corebridge Financial, have delivered strong or steady performance, supporting the fund’s returns.
Sector Diversification Across the U.S. MarketThe fund spreads its investments across multiple sectors such as health care, financials, technology, consumer stocks, and industrials, which helps reduce the impact of weakness in any single industry.
Negative Factors
Higher Expense RatioThe ETF charges a relatively high expense ratio, which means more of the fund’s returns are eaten up by fees compared with many low-cost index funds.
Concentration in U.S. StocksWith almost all assets invested in U.S. companies, the fund offers little geographic diversification and is heavily exposed to the U.S. economy and market cycles.
Notable Lagging HoldingsSome key positions such as Cognizant, Fresenius Medical Care, and Dollar General have shown weak or negative performance, which can drag on the fund’s overall results if the trend continues.

PZLV vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%25%30%SPY+14.55%PZLV+28.09%May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
73.18M
Region
North America
Expense Ratio
0.60%
Beta
0.31
Issuer
Pzena
Inception Date
Apr 01, 2026
Dividend Yield
N/A
Asset Class
Equity
Index Tracked
No Underlying Index

PZLV Summary

Pzena U.S. Large Cap Value ETF (PZLV) is an actively managed fund that focuses on large, established U.S. companies that appear undervalued based on their earnings and assets. It follows a value investing theme rather than tracking a fixed index, with major holdings in sectors like health care, financials, and technology. Well-known companies in the fund include CVS Health and Humana. Investors might consider PZLV if they want long-term growth by investing in solid companies that may be temporarily out of favor. A key risk is that value stocks can stay cheap for a long time, and the ETF’s price can go up and down with the overall stock market.

How much will it cost me?

This ETF has an expense ratio of 0.60%, which means you’ll pay about $6 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed, paying a professional team to research and pick value stocks rather than simply tracking an index.

What would affect this ETF?

This ETF could benefit if the U.S. economy stays healthy, interest rates stabilize or fall, and investor sentiment shifts toward value stocks, which may help its large health care, financial, and technology holdings as well as companies like Baxter, Humana, and Wells Fargo. On the downside, higher interest rates, pressure on bank profits, changes to health care regulation, or a slowdown in consumer spending could hurt its financial and health care exposure and weigh on top holdings such as CVS, Capital One, and Dollar General.

PZLV Top 10 Holdings

PZLV is leaning hard into U.S. health care and financial value names, and that’s where most of the action is. Humana has been a clear bright spot, rising steadily and giving the fund a healthy tailwind, while CDW and Tyson Foods are also quietly pulling their weight. On the flip side, Baxter and Fresenius Medical Care look more like problem children, with mixed to lagging trends that cap some of the upside. Cognizant’s rebound efforts remain uneven, underscoring that this is a concentrated, U.S.-only value bet with a few key stocks setting the tone.

PZLV top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
BAXBAXBaxter International5.06%$3.70M$13.35B38.02%45Neutral
CRBGCRBGCorebridge Financial, Inc.4.66%$3.41M$15.94B24.79%67Neutral
HUMHUMHumana4.33%$3.17M$54.05B90.08%69Neutral
FMSFMSFresenius Medical Care3.80%$2.78M$11.75B-7.05%65Neutral
CDWCDWCDW3.50%$2.56M$21.42B16.97%62Neutral
UHSUHSUniversal Health3.33%$2.44M$11.19B-14.72%74Outperform
CVSCVSCVS Health3.23%$2.37M$114.32B12.76%64Neutral
RHIRHIRobert Half3.18%$2.32M$4.30B52.84%60Neutral
TSNTSNTyson Foods3.11%$2.27M$20.28B8.32%69Neutral
DGDGDollar General3.06%$2.24M$29.59B28.75%73Outperform

PZLV Technical Analysis

Technical Analysis SentimentPositive
Last Price32.15

Price Trends

50DMA31.07Positive
100DMA30.71Positive

Market Momentum

MACD0.34Negative
RSI57.94Neutral
STOCH59.56Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PZLV, the sentiment is Positive. The current price of 32.15 is above the 20-day moving average (MA) of 31.78, above the 50-day MA of 31.07, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.34 indicates Negative momentum. The RSI at 57.94 is Neutral, neither overbought nor oversold. The STOCH value of 59.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PZLV.

PZLV Peer Comparison

Comparison Results

PZLV against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
PZLVPZLV$32.15$35.00(8.85% Upside)$73.18M0.60%68Neutral
PRXVPRXV$36.83$42.31(14.89% Upside)$97.40M0.36%72Outperform
MAVFMAVF$141.05$167.40(18.68% Upside)$93.69M0.75%74Outperform
NSIVNSIV$26.14$29.70(13.63% Upside)$74.39M0.38%72Outperform
DHLXDHLX$14.29$16.27(13.87% Upside)$69.44M0.55%73Outperform
MDLVMDLV$32.21$34.70(7.74% Upside)$48.85M0.58%68Neutral

Performance Comparison

0%10%20%PZLVPRXVMAVFNSIVDHLXMDLVMay '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PZLV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PZLVPzena U.S. Large Cap Value ETF32.157.0528.09%
PRXVPraxis Impact Large Cap Value ETF36.837.9627.58%
MAVFMatrix Advisors Value ETF141.0525.9522.55%
NSIVNorth Square Disciplined Value ETF26.141.054.20%
DHLXDiamond Hill Large Cap Concentrated ETF14.291.7614.07%
MDLVMorgan Dempsey Large Cap Value ETF32.215.0418.53%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.